201 related articles for article (PubMed ID: 16251873)
1. Engineering T cells for cancer therapy.
Mansoor W; Gilham DE; Thistlethwaite FC; Hawkins RE
Br J Cancer; 2005 Nov; 93(10):1085-91. PubMed ID: 16251873
[TBL] [Abstract][Full Text] [Related]
2. Improving the efficacy and safety of engineered T cell therapy for cancer.
Shi H; Liu L; Wang Z
Cancer Lett; 2013 Jan; 328(2):191-7. PubMed ID: 23022475
[TBL] [Abstract][Full Text] [Related]
3. Genetically modulating T-cell function to target cancer.
Merhavi-Shoham E; Haga-Friedman A; Cohen CJ
Semin Cancer Biol; 2012 Feb; 22(1):14-22. PubMed ID: 22210183
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.
Berry LJ; Moeller M; Darcy PK
Tissue Antigens; 2009 Oct; 74(4):277-89. PubMed ID: 19775368
[TBL] [Abstract][Full Text] [Related]
5. Antigen choice in adoptive T-cell therapy of cancer.
Offringa R
Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
[TBL] [Abstract][Full Text] [Related]
6. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
[TBL] [Abstract][Full Text] [Related]
7. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
8. Making and circumventing tolerance to cancer.
Kammertoens T; Blankenstein T
Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
[TBL] [Abstract][Full Text] [Related]
9. Supernatural T cells: genetic modification of T cells for cancer therapy.
Kershaw MH; Teng MW; Smyth MJ; Darcy PK
Nat Rev Immunol; 2005 Dec; 5(12):928-40. PubMed ID: 16322746
[TBL] [Abstract][Full Text] [Related]
10. Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy.
Kammula US; Serrano OK
J Transl Med; 2008 Oct; 6():60. PubMed ID: 18937837
[TBL] [Abstract][Full Text] [Related]
11. Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy.
Thistlethwaite F; Mansoor W; Gilham DE; Hawkins RE
Curr Opin Mol Ther; 2005 Feb; 7(1):48-55. PubMed ID: 15732529
[TBL] [Abstract][Full Text] [Related]
12. Preclinical development of T cell receptor gene therapy.
Bendle GM; Haanen JB; Schumacher TN
Curr Opin Immunol; 2009 Apr; 21(2):209-14. PubMed ID: 19321326
[TBL] [Abstract][Full Text] [Related]
13. Circumventing T-cell tolerance to tumour antigens.
Kessels HW; de Visser KE; Kruisbeek AM; Schumacher TN
Biologicals; 2001; 29(3-4):277-83. PubMed ID: 11851328
[TBL] [Abstract][Full Text] [Related]
14. Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.
Eshhar Z
Curr Opin Mol Ther; 2010 Feb; 12(1):55-63. PubMed ID: 20140817
[TBL] [Abstract][Full Text] [Related]
15. T-cell engineering for cancer immunotherapy.
Sadelain M
Cancer J; 2009; 15(6):451-5. PubMed ID: 20010162
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumours by adoptive transfer of immune cells.
Macary PA; Too CT; Dai X
Clin Exp Pharmacol Physiol; 2006; 33(5-6):569-74. PubMed ID: 16700896
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
Chicaybam L; Sodré AL; Bonamino M
Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy of solid tumor: perspectives on vaccine and cell therapy].
Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2043-50. PubMed ID: 23259373
[TBL] [Abstract][Full Text] [Related]
19. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
Melief CJ; Kast WM
Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
[TBL] [Abstract][Full Text] [Related]
20. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
